Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 6, 2011, Pages 908-915

  Eissa, Hesham ^a,b,c   Gooley, Ted A ^a,d   Sorror, Mohamed L ^a   Nguyen, Franchesca ^a   Scott, Bart L ^a,d   Doney, Kristine ^a,d   Loeb, Keith R ^a,d   Martin, Paul J ^a,d   Pagel, John M ^a,d   Radich, Jerry P ^a,d   Sandmaier, Brenda M ^a,d   Warren, E Houston ^a,d   Storb, Rainer ^a,d   Appelbaum, Frederick R ^a,d   Deeg, H Joachim ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Nasser Institute and Hospital for Research and Treatment   (Egypt)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CMML; Comorbidity; Cytogenetics; Hematopoietic cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TREOSULFAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; COMORBIDITY; CYTOGENETICS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELOMONOCYTIC LEUKEMIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE FREE SURVIVAL; STEM CELL;

AGE FACTORS; BONE MARROW TRANSPLANTATION; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79956054105     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.09.018     Document Type: Article

References (29)

1. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
2. Germing U., Strupp C., Knipp S., et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 2007, 92:974-977.
3. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. [erratum appears in Blood 1998;91(3):1100].
4. Pich A., Riera L., Sismondi F., et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol 2009, 62:798-801.
5. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373.
6. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
7. Such E., Cervera J., Nomdedeu B., et al. A new prognostic scoring system including transfusion dependency and cytogenetic abnormalities for patients with chronic myelomonocytic leukemia. Blood 2009, 114:695-696.
8. Fukuhara T., Kakinoki Y. Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification. Rinsho Byori Jpn J Clin Pathol 2006, 54:243-249. [Japanese].
9. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008, 14:246-255.
10. Elliott M.A., Tefferi A., Hogan W.J., et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006, 37:1003-1008.
11. Kerbauy D.M.B., Chyou F., Gooley T., et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005, 11:713-720.
12. Warlick E.D., Cioc A., DeFor T., Dolan M., Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009, 15:30-38.
13. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
14. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
15. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998, 92:3515-3520.
16. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. prepublished online May 25, 2010; doi:. doi:10.1016/j.bbmt.2010.05.007.
17. Martin P.J., Pei J., Gooley T., et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004, 10:552-560.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
19. Martin P., Nash R., Sanders J., et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1998, 21:273-279.
20. Benesch M., Deeg H.J. Acute graft-versus-host disease. Hematopoietic Stem Cell Transplantation 2008, 589-620. Humana Press, Totowa, NJ. R.J. Soiffer (Ed.).
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Flowers M.E.D., Storer B.E., Lee S.J., et al. Risk factors for the development of acute and National Institute of Health (NIH) chronic graft-versus-host disease (GVHD). Blood 2009, 114:146.
23. Wattel E., Guerci A., Hecquet B., et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 1996, 88:2480-2487.
24. Kurzrock R., Albitar M., Cortes J.E., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004, 22:1287-1292.
25. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
26. Mittal P., Saliba R.M., Giralt S.A., et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004, 33:1005-1009.
27. Kroger N., Zabelina T., Guardiola P., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002, 118:67-73.
28. Krishnamurthy P, Lim ZY, Nagi W, et al. Allogeneic haematopoietic SCT for chonic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant. prepublished online January 25, 2010; doi:. http://10.1038/bmt.2009.375.
29. Benesch M., McDonald G.B., Schubert M., Appelbaum F.R., Deeg H.J. Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant 2003, 32:1071-1075.